摘要
体内外实验及临床应用,证明LAK细胞具有抗肿瘤抗转移作用,作用与LAK细胞输入的数量、次数及rIL-2的投入有关。国外多采用患者自身PBL作为LAK效应细胞的前体细胞,为此需反复地从患者外周血中分离白细胞,以获得大量前体细胞。这既给患者增加负担,又常引起许多副作用。虽然TIL可作为LAK样前体细胞应用于临床,但从实体瘤中分离TIL操作复杂,又消耗酶制剂。
Ten patients with malignant ascites due to advanced ovarian cancer were treatedby i. p. adoptive transfer of autologous LAN cells derived from lymphocytes in ascitesin presenoe of rIL-2. rIL-2 was administered 7 days before and after the transferof LAK cells. The amount of ascites and number of tumor cells in ascites wassignificantly decreased and the number of Iymphocytes in ascites was significantlyincreased in 8 responders, but not in other 2 cases. During the 4 month follow-up nochanges in amount of ascites were found in 6 responders, but increased in other 2responders. No side effect was encountered in all 10 patients. This preliminary resultindicated that the treatment was effective, safe and feasible.
出处
《肿瘤》
CAS
CSCD
北大核心
1989年第5期203-205,共3页
Tumor
